Wedbush Weighs in on Xencor’s Q2 Earnings (NASDAQ:XNCR)
Xencor, Inc. (NASDAQ:XNCR – Free Report) – Investment analysts at Wedbush cut their Q2 2025 earnings estimates for Xencor in a research report issued on Wednesday, May 7th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($0.78) for the quarter, down from their previous forecast of ($0.60). […]
Xencor, Inc. (NASDAQ:XNCR – Free Report) – Investment analysts at Wedbush cut their Q2 2025 earnings estimates for Xencor in a research report issued on Wednesday, May 7th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($0.78) for the quarter, down from their previous forecast of ($0.60). […]
